Illumina and Genomas to Co-Develop SNP, Haplotype Panels for Metabolic Syndrome | GenomeWeb

NEW YORK, July 20 (GenomeWeb News) - Illumina and Genomas said today that they will co-develop SNP- and haplotype-based gene marker panels related to metabolic syndrome that Illumina may commercialize upon validation.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.